DGIdb - SELICICLIB Drug Record

SELICICLIB chembl:CHEMBL14762 Antineoplastic

Alternate Names:

NSC-701554
SELICICLIB
AL-39256
CYC-202
R-ROSCOVITINE
ROSCOVITINE
CYC202
(2R)-2-((9-(1-METHYLETHYL)-6-((PHENYLMETHYL)AMINO)-9H-PURIN-2-YL)AMINO)-1-BUTANOL
(2R)-2-{[6-(BENZYLAMINO)-9-(1-METHYLETHYL)-9H-PURIN-2-YL]AMINO}BUTAN-1-OL
(R)-ROSCOVITINE
(R)-2-((9-(1-METHYLETHYL)-6-((PHENYLMETHYL)AMINO)-9H-PURIN-2-YL)AMINO)-1-BUTANOL
2-(R)-(1-ETHYL-2-HYDROXYETHYLAMINO)-6-BENZYLAMINO-9-ISOPROPYLPURINE
chemidplus:186692-46-6
pubchem.compound:160355
drugbank:06195
chembl:CHEMBL14762

Drug Info:

Drug Class	Kinase Inhibitors
FDA Approval	not approved
Drug Class	small molecule
Drug Indications	antineoplastic agent
Drug Type	small molecule
Drug Groups	investigational
Drug Categories	anti-infective agents
Drug Categories	antineoplastic agents
Drug Categories	enzyme inhibitors
Drug Categories	heterocyclic compounds, fused-ring
Drug Categories	protein kinase inhibitors
Drug Categories	purines

(5 More Sources)

Publications:

Iurisci I et al., 2006, Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor., Cancer Res
Heathcote DA et al., 2010, A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration., J Med Chem
Jorda R et al., 2011, Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity., J Med Chem
Jabbour-Leung et al., 2016, Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer., Mol. Cancer Ther.
Slovackova et al., 2012, Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53., Neoplasma

SELICICLIB CCNB1

Interaction Score: 2.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21080703

Sources:
DTC
SELICICLIB CSNK1E

Interaction Score: 0.95

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17108108

Sources:
DrugBank
SELICICLIB CDK7

Interaction Score: 0.87

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Novel Target

Trial Name seliciclib, R-roscovitine, CYC202

Mechanism of Interaction Cyclin-dependent kinase 7 inhibitor

PMIDs:
17108108

Sources:
DrugBank MyCancerGenome TdgClinicalTrial ChemblInteractions TTD
SELICICLIB CDK9

Interaction Score: 0.87

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclin-dependent kinase 9 inhibitor

Direct Interaction yes

Direct Interaction? True

PMIDs:
17108108

Sources:
DrugBank MyCancerGenome TdgClinicalTrial ChemblInteractions GuideToPharmacology
SELICICLIB CCND1

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21080703

Sources:
DTC
SELICICLIB RB1

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21417417

Sources:
DTC
SELICICLIB CDK1

Interaction Score: 0.26

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclin-dependent kinase 1 inhibitor

Direct Interaction yes

PMIDs:
17108108

Sources:
DrugBank ChemblInteractions TTD
SELICICLIB CCNA2

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21080703

Sources:
DTC
SELICICLIB CDK2

Interaction Score: 0.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Novel Target

Trial Name seliciclib, R-roscovitine, CYC202

Details of the Assay for Interaction CDK2/cyclin A complex used in assay

PMIDs:
21080703 17108108

Sources:
DTC DrugBank MyCancerGenome TdgClinicalTrial ChemblInteractions GuideToPharmacology TTD
SELICICLIB MAPK3

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17108108

Sources:
DrugBank
SELICICLIB CDK5

Interaction Score: 0.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclin-dependent kinase 5 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
SELICICLIB TP53

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type non-small cell lung carcinoma

Response Type decreased response

Approval Status Preclinical - Cell culture

PMIDs:
21417417 26826118 22862161

Sources:
DTC JAX-CKB
SELICICLIB MAPK1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17108108

Sources:
DrugBank
SELICICLIB SMN2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SELICICLIB SMN1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

DrugBank: DB06195
- Version: 5.1.7
Alternate Names:

SELICICLIB DrugBank Drug Name

186692-46-6 CAS Number

CHEMBL14762 ChEMBL ID

Drug Info:

Drug Type small molecule

Drug Groups investigational

Drug Categories anti-infective agents

Publications:

Iurisci I et al., 2006, Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor., Cancer Res
MyCancerGenome: SELICICLIB
- Version: 20-Jun-2017
Alternate Names:

CYC202 Development Name

SELICICLIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:
TdgClinicalTrial: SELICICLIB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class small molecule

FDA Approval not approved

Publications:

DTC: SELICICLIB

Version: 02-September-2020

Alternate Names:

CHEMBL14762 ChEMBL Drug ID

Drug Info:

Publications:

Heathcote DA et al., 2010, A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration., J Med Chem

Jorda R et al., 2011, Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity., J Med Chem

JAX-CKB: Seliciclib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Slovackova et al., 2012, Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53., Neoplasma

Jabbour-Leung et al., 2016, Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer., Mol. Cancer Ther.

TTD: R-roscovitine
- Version: 2020.06.01
Alternate Names:

D05ADP TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178102657
- Version: 29-September-2020
Alternate Names:

SELICICLIB GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL14762
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL14762
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Novel drug target	Novel Target
Trial Name	seliciclib, R-roscovitine, CYC202
Mechanism of Interaction	Cyclin-dependent kinase 7 inhibitor

Mechanism of Interaction	Cyclin-dependent kinase 9 inhibitor
Direct Interaction	yes
Direct Interaction?	True

Mechanism of Interaction	Cyclin-dependent kinase 1 inhibitor
Direct Interaction	yes

Mechanism of Interaction	Cyclin-dependent kinase 5 inhibitor
Direct Interaction	yes

Indication/Tumor Type	non-small cell lung carcinoma
Response Type	decreased response
Approval Status	Preclinical - Cell culture

SELICICLIB	DrugBank Drug Name
186692-46-6	CAS Number
CHEMBL14762	ChEMBL ID

SELICICLIB Drug Record

SELICICLIB chembl:CHEMBL14762 Antineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21080703

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17108108

Sources: DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Novel Target Trial Name seliciclib, R-roscovitine, CYC202 Mechanism of Interaction Cyclin-dependent kinase 7 inhibitor

PMIDs: 17108108

Sources: DrugBank MyCancerGenome TdgClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Cyclin-dependent kinase 9 inhibitor Direct Interaction yes Direct Interaction? True

PMIDs: 17108108

Sources: DrugBank MyCancerGenome TdgClinicalTrial ChemblInteractions GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21080703

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21417417

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Cyclin-dependent kinase 1 inhibitor Direct Interaction yes

PMIDs: 17108108

Sources: DrugBank ChemblInteractions TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21080703

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Novel Target Trial Name seliciclib, R-roscovitine, CYC202 Details of the Assay for Interaction CDK2/cyclin A complex used in assay

PMIDs: 21080703 17108108

Sources: DTC DrugBank MyCancerGenome TdgClinicalTrial ChemblInteractions GuideToPharmacology TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17108108

Sources: DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Cyclin-dependent kinase 5 inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type non-small cell lung carcinoma Response Type decreased response Approval Status Preclinical - Cell culture

PMIDs: 21417417 26826118 22862161

Sources: DTC JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17108108

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

DrugBank: DB06195

Alternate Names: SELICICLIB DrugBank Drug Name 186692-46-6 CAS Number CHEMBL14762 ChEMBL ID

Drug Info: Drug Type small molecule Drug Groups investigational Drug Categories anti-infective agents

Publications: Iurisci I et al., 2006, Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor., Cancer Res

MyCancerGenome: SELICICLIB

Alternate Names: CYC202 Development Name SELICICLIB Generic Name

Drug Info: Drug Class Kinase Inhibitors

Publications:

TdgClinicalTrial: SELICICLIB

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class small molecule FDA Approval not approved

Publications:

DTC: SELICICLIB

Alternate Names: CHEMBL14762 ChEMBL Drug ID

Drug Info:

Interaction Types & Directionality:

n/a

PMIDs:
21080703

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
17108108

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Novel Target

Trial Name seliciclib, R-roscovitine, CYC202

Mechanism of Interaction Cyclin-dependent kinase 7 inhibitor

PMIDs:
17108108

Sources:
DrugBank MyCancerGenome TdgClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclin-dependent kinase 9 inhibitor

Direct Interaction yes

Direct Interaction? True

PMIDs:
17108108

Sources:
DrugBank MyCancerGenome TdgClinicalTrial ChemblInteractions GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
21080703

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
21417417

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclin-dependent kinase 1 inhibitor

Direct Interaction yes

PMIDs:
17108108

Sources:
DrugBank ChemblInteractions TTD

Interaction Types & Directionality:

n/a

PMIDs:
21080703

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Novel Target

Trial Name seliciclib, R-roscovitine, CYC202

Details of the Assay for Interaction CDK2/cyclin A complex used in assay

PMIDs:
21080703 17108108

Sources:
DTC DrugBank MyCancerGenome TdgClinicalTrial ChemblInteractions GuideToPharmacology TTD

Interaction Types & Directionality:

n/a

PMIDs:
17108108

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cyclin-dependent kinase 5 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type non-small cell lung carcinoma

Response Type decreased response

Approval Status Preclinical - Cell culture

PMIDs:
21417417 26826118 22862161

Sources:
DTC JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
17108108

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

SELICICLIB DrugBank Drug Name

186692-46-6 CAS Number

CHEMBL14762 ChEMBL ID

Drug Info:

Drug Type small molecule

Drug Groups investigational

Drug Categories anti-infective agents

Publications:

Iurisci I et al., 2006, Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor., Cancer Res

Alternate Names:

CYC202 Development Name

SELICICLIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

Drug Info:

Drug Indications antineoplastic agent

Drug Class small molecule

FDA Approval not approved

Alternate Names:

CHEMBL14762 ChEMBL Drug ID

Alternate Names:

D05ADP TTD Drug ID

Alternate Names:

SELICICLIB GuideToPharmacology Ligand Name